Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study
Eptinezumab may be an effective and well-tolerated option for some treatment-refractory migraine patients unresponsive to subcutaneous CGRP-(R) mAbs.
Authors
- Ja Bin Hong (ORCID: https://orcid.org/0009-0002-1541-0291)
- Bianca Raffaelli (ORCID: https://orcid.org/0000-0001-9758-1494)
- Uwe Reuter (ORCID: https://orcid.org/0000-0002-8527-0725)
- Mira Pauline Fitzek (ORCID: https://orcid.org/0000-0003-0299-4830)
- Kristin Sophie Lange (ORCID: https://orcid.org/0000-0002-8056-8514)
- Lucas Hendrik Overeem (ORCID: https://orcid.org/0000-0003-2057-7184)
- Paul Triller (ORCID: https://orcid.org/0000-0002-7935-2089)
- Virginia N. Blessing
Institutions
- Universitätsmedizin Greifswald (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Cephalalgia
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1177/03331024241288875
- Citations
- 7
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.70
Funders
- Lundbeckfonden